MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413862 | Name: Soravtansine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Soravtansine is used in the treatment of Cancer

Chemical Structure

Soravtansine
Soravtansine
CAS#1461704-01-7

Theoretical Analysis

MedKoo Cat#: 413862

Name: Soravtansine

CAS#: 1461704-01-7

Chemical Formula: C42H58ClN3O14S3

Exact Mass: 959.2769

Molecular Weight: 960.56

Elemental Analysis: C, 52.52; H, 6.09; Cl, 3.69; N, 4.37; O, 23.32; S, 10.01

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Soravtansine; DM4-Sulfo-TBA
IUPAC/Chemical Name
(2RS,12S)-14-((1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo(19.3.1.110.14.03.5)hexacosa-10,12,14(26),16,18-pentaen-6-yl)-7,7,11,12-tetramethyl-10,13-dioxo-2-sulfonyl-14-oxa-5,6-dithia-11-azatetradecanoic acid
InChi Key
GAULQIAKUFMENA-WHCGHJAJSA-N
InChi Code
InChI=1S/C42H58ClN3O14S3/c1-23-12-11-13-31(57-10)42(53)22-29(58-39(52)44-42)24(2)36-41(6,60-36)32(21-34(48)46(8)27-19-26(18-23)20-28(56-9)35(27)43)59-38(51)25(3)45(7)33(47)14-16-40(4,5)62-61-17-15-30(37(49)50)63(54)55/h11-13,19-20,24-25,29,31-32,36,53H,14-18,21-22H2,1-10H3,(H,44,52)(H,49,50)/b13-11+,23-12+/t24-,25+,29+,31-,32+,36+,41+,42+/m1/s1
SMILES Code
O=C(O)C(CCSSC(C)(C)CCC(N(C)[C@@H](C)C(O[C@@H](CC(N(C)C1=C(Cl)C(OC)=CC(C/C(C)=C/C=C/[C@@H](OC)[C@]2(O)N3)=C1)=O)[C@]4(C)O[C@@]4([H])[C@H](C)[C@@](C2)([H])OC3=O)=O)=O)=S(=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 960.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Vergote I, Ponte JF, Birrer MJ. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 2018 Jan;14(2):123-136. doi: 10.2217/fon-2017-0379. Epub 2017 Nov 3. PMID: 29098867. 2: O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020 May;157(2):379-385. doi: 10.1016/j.ygyno.2020.01.037. Epub 2020 Feb 18. PMID: 32081463. 3: von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce- Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. PMID: 30516102. 4: Moore KN, Vergote I, Oaknin A, Colombo N, Banerjee S, Oza A, Pautier P, Malek K, Birrer MJ. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future Oncol. 2018 Jul;14(17):1669-1678. doi: 10.2217/fon-2017-0646. Epub 2018 Feb 9. PMID: 29424243. 5: Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017 Jun 17;389(10087):2415-2429. doi: 10.1016/S0140-6736(16)32417-5. Epub 2016 Dec 7. PMID: 27939064. 6: Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. doi: 10.1038/nrd.2016.268. Epub 2017 Mar 17. PMID: 28303026. 7: Rinnerthaler G, Gampenrieder SP, Greil R. HER2 Directed Antibody-Drug- Conjugates beyond T-DM1 in Breast Cancer. Int J Mol Sci. 2019 Mar 5;20(5):1115. doi: 10.3390/ijms20051115. PMID: 30841523; PMCID: PMC6429068. 8: Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 1;35(10):1112-1118. doi: 10.1200/JCO.2016.69.9538. Epub 2016 Dec 28. PMID: 28029313; PMCID: PMC5559878. 9: Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014 Jan;17(1):1-12. doi: 10.1007/s10120-013-0252-z. Epub 2013 Apr 7. PMID: 23563986; PMCID: PMC3889288. 10: Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014 Mar 5;16(2):209. doi: 10.1186/bcr3621. PMID: 24887180; PMCID: PMC4058749.